Hematopathology — MCQs

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 161: Which of the following statements about coagulation factor VII is not true?

A. Deficiency is inherited as an Autosomal Recessive trait.
B. Deficiency is associated with prolonged APTT. (Correct Answer)
C. Deficiency can be managed by Fresh Frozen Plasma.
D. Has a short half-life in comparison to Hageman factor (XII).

Explanation: **Explanation:** Coagulation Factor VII is a key component of the **Extrinsic Pathway** of the coagulation cascade. Understanding its unique position is crucial for solving this question. **Why Option B is the correct answer (False statement):** The Activated Partial Thromboplastin Time (APTT) measures the integrity of the **Intrinsic** and **Common** pathways (Factors XII, XI, IX, VIII, X, V, II, and I). Factor VII is exclusively involved in the **Extrinsic Pathway**, which is measured by Prothrombin Time (PT). Therefore, a deficiency in Factor VII results in a **prolonged PT with a normal APTT** [1]. **Analysis of other options:** * **Option A:** Factor VII deficiency is indeed an **Autosomal Recessive** bleeding disorder, making this statement true. * **Option C:** Fresh Frozen Plasma (FFP) contains all coagulation factors, including Factor VII, and is a standard treatment for replacement in deficiency states. * **Option D:** Factor VII has the **shortest half-life** (approximately 4–6 hours) of all clotting factors. In contrast, Factor XII (Hageman factor) has a much longer half-life (approximately 48–52 hours). **High-Yield Clinical Pearls for NEET-PG:** * **Shortest Half-life:** Factor VII is the first factor to decrease in Vitamin K deficiency or liver disease, making PT the most sensitive indicator of liver synthetic function [1]. * **Isolated PT Prolongation:** Always consider Factor VII deficiency or early Vitamin K antagonism (Warfarin therapy) [1]. * **Treatment:** Recombinant activated Factor VII (rFVIIa) is often used for "inhibitor" patients in Hemophilia A/B and severe FVII deficiency. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 582-583.

Question 162: Eighty-five percent of aggressive lymphomas exhibit which cell type?

A. Follicular small cleaved cell lymphoma
B. Diffuse small lymphocytic lymphoma
C. Diffuse large cell lymphoma (Correct Answer)
D. Adult T-cell leukemia-lymphoma

Explanation: **Explanation:** The correct answer is **Diffuse Large B-Cell Lymphoma (DLBCL)**. **Why it is correct:** Non-Hodgkin Lymphomas (NHLs) are broadly categorized into indolent (low-grade) and aggressive (high-grade) types. **Diffuse Large B-Cell Lymphoma** is the most common histological subtype of NHL worldwide, accounting for approximately 30–40% of all cases. Among the **aggressive lymphomas**, it is the predominant type, representing roughly **85%** of cases in this category [1]. It is characterized by large B-cells with prominent nucleoli and a high proliferation index (Ki-67) [1]. **Why other options are incorrect:** * **A. Follicular small cleaved cell lymphoma:** This is an **indolent** (low-grade) lymphoma [3]. While it is the second most common NHL, it is slow-growing and does not fall under the "aggressive" category unless it transforms into DLBCL (Richter’s transformation). * **B. Diffuse small lymphocytic lymphoma (SLL):** This is the nodal counterpart of Chronic Lymphocytic Leukemia (CLL). It is a classic **indolent** lymphoma characterized by small, mature lymphocytes. * **C. Adult T-cell leukemia-lymphoma (ATLL):** While highly aggressive, it is a rare T-cell malignancy associated with the **HTLV-1 virus**. It does not constitute the majority of aggressive lymphomas. **NEET-PG High-Yield Pearls:** * **Most common NHL overall:** Diffuse Large B-Cell Lymphoma (DLBCL). * **Most common indolent NHL:** Follicular Lymphoma [3]. * **Genetic Hallmark of DLBCL:** Often involves mutations in the *BCL6* gene (3q27) or *BCL2* translocation t(14;18) [2]. * **Treatment:** The standard of care is the **R-CHOP** regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone). * **Prognosis:** Despite being aggressive, DLBCL is potentially curable with intensive chemotherapy, unlike many indolent lymphomas [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 604-605. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 563-564. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604.

Question 163: Cyanosis cannot occur in severe anaemia because

A. Anaemic blood has a higher O2 carrying capacity per gram of Hb
B. It requires a critical concentration of reduced Hb in blood (Correct Answer)
C. Patient improves his alveolar oxygen as a compensation for anaemia
D. There is an increased blood flow through the skin

Explanation: **Explanation:** **1. Why the correct answer is right:** Cyanosis is a clinical sign characterized by a bluish discoloration of the skin and mucous membranes. It occurs only when the absolute concentration of **reduced (deoxygenated) hemoglobin** in the capillary blood exceeds **5 g/dL**. In severe anemia, the total hemoglobin (Hb) level is significantly low (e.g., 5-6 g/dL) [1]. For a patient with 5 g/dL of total Hb to exhibit cyanosis, nearly 100% of their hemoglobin would need to be in the reduced state. However, such a level of hypoxemia is incompatible with life, as the patient would succumb to tissue hypoxia long before the critical threshold of 5 g/dL of reduced Hb is reached. Therefore, cyanosis cannot manifest in severe anemia despite profound hypoxia. **2. Why the incorrect options are wrong:** * **Option A:** Anaemic blood does not have a higher O2 carrying capacity; in fact, the total O2 content is reduced because it is directly proportional to the Hb concentration. * **Option C:** While the body compensates for anemia (e.g., increased cardiac output, increased 2,3-BPG), improving alveolar oxygen does not prevent cyanosis if the reduced Hb threshold is met. * **Option D:** In anemia, blood is often shunted away from the skin to vital organs (vasoconstriction), which may cause pallor [1], but it does not explain the absence of cyanosis. **3. Clinical Pearls for NEET-PG:** * **The Magic Number:** 5 g/dL of reduced Hb is the threshold for central cyanosis. * **Polycythemia:** Patients with polycythemia develop cyanosis more easily (at higher O2 saturation levels) because they have an abundance of Hb. * **Anemia vs. Cyanosis:** Anemia is a quantitative deficiency of Hb; Cyanosis is a qualitative reflection of deoxygenated Hb. * **Methemoglobinemia:** Can cause "pseudocyanosis" even at low concentrations (1.5 g/dL of met-Hb) because of its dark pigment. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 638-639.

Question 164: According to the FAB classification, what is the minimum percentage of blast cells required for the diagnosis of Acute Myeloid Leukemia (AML)?

A. 20%
B. 30% (Correct Answer)
C. 10%
D. 40%

Explanation: ### Explanation The diagnosis of Acute Myeloid Leukemia (AML) relies on the quantification of blast cells in the bone marrow or peripheral blood. The threshold for diagnosis has evolved over time through two major classification systems: **1. Why 30% is the Correct Answer (FAB Classification):** The **French-American-British (FAB) classification**, established in the 1970s, set the diagnostic threshold for AML at **≥30% blasts**. This system primarily used morphology and cytochemical staining (like Myeloperoxidase) to categorize leukemias. Under FAB criteria, if blasts were between 21% and 29%, the condition was classified as Refractory Anemia with Excess Blasts in Transformation (RAEB-T), a sub-type of Myelodysplastic Syndrome (MDS). **2. Analysis of Incorrect Options:** * **Option A (20%):** This is the current threshold according to the **WHO Classification** [1], [2]. The WHO lowered the requirement to **≥20% blasts** to allow for earlier treatment [1]. Note: If specific cytogenetic abnormalities like t(8;21), inv(16), or t(15;17) [2] are present, the diagnosis of AML is made regardless of the blast percentage. * **Option C (10%):** This does not meet the criteria for AML in either system. 10-19% blasts typically categorize a patient as having MDS (specifically RAEB-2). * **Option D (40%):** This value is arbitrarily high and has never been a standard diagnostic cutoff for AML. **Clinical Pearls for NEET-PG:** * **FAB Criteria:** ≥30% blasts (Historical/Morphological focus). * **WHO Criteria:** ≥20% blasts (Modern/Genetic focus) [1]. * **Exception:** Presence of **Auer rods** is pathognomonic for myeloblasts (AML), most commonly seen in M2 and M3 subtypes [2]. * **M3 (APML):** Associated with t(15;17) and carries a high risk of DIC; treated with ATRA [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 613-614. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 620.

Question 165: Leukocytopenia is seen in which of the following conditions?

A. Influenza
B. Agranulocytosis
C. Liver cirrhosis
D. All of the above (Correct Answer)

Explanation: **Explanation:** Leukocytopenia refers to a decrease in the total white blood cell (WBC) count below the normal range (usually <4,000/mm³). This condition can result from decreased production in the bone marrow, increased peripheral destruction, or sequestration in the spleen. * **Influenza (Viral Infections):** While bacterial infections typically cause leukocytosis, many viral infections like influenza, measles, and hepatitis often lead to transient leukopenia [1]. This occurs due to the redistribution of lymphocytes and bone marrow suppression by inflammatory cytokines (e.g., Interferons). * **Agranulocytosis:** This is a severe reduction in the granulocyte count (specifically neutrophils <500/mm³). It is a definitive cause of leukocytopenia and is often drug-induced (e.g., Clozapine, Antithyroid drugs) or due to bone marrow failure [2]. * **Liver Cirrhosis:** Cirrhosis leads to portal hypertension, which causes congestive splenomegaly. The enlarged spleen sequesters and destroys circulating blood cells, including WBCs, a phenomenon known as **hypersplenism** [3]. **Conclusion:** Since all three conditions can lead to a reduced total leukocyte count through different mechanisms, **Option D** is correct. **High-Yield Clinical Pearls for NEET-PG:** * **Kostmann Syndrome:** A congenital form of severe agranulocytosis. * **Felty’s Syndrome:** A triad of Rheumatoid Arthritis, Splenomegaly, and Neutropenia [3]. * **Typhoid Fever:** A classic bacterial exception that presents with **leukopenia** rather than leukocytosis [1]. * **Drugs causing Agranulocytosis:** Remember the mnemonic **"CCC"**—Clozapine, Carbamazepine, and Colchicine (along with PTU/Methimazole) [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 110-111. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Heart, pp. 590-592. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 604-605.

Question 166: Arrange the following blood components in descending order of their shelf life:

A. Platelets at 20 degrees C
B. Fresh Frozen Plasma (FFP) at -18 degrees C
C. Whole blood with CPDA-1 solution at 4 degrees C
D. Whole blood with CPD solution at 4 degrees C (Correct Answer)

Explanation: To master blood banking for NEET-PG, it is essential to memorize the specific shelf lives determined by preservatives and storage temperatures. The shelf life of blood components is primarily dictated by the metabolic rate of cells and the biochemical stability of plasma proteins. ### **Analysis of Components (Descending Order of Shelf Life):** 1. **Fresh Frozen Plasma (FFP) at -18°C:** This has the longest shelf life of **1 year**. Freezing preserves coagulation factors (especially V and VIII) by halting enzymatic degradation. 2. **Whole Blood with CPDA-1 at 4°C:** The addition of **Adenine** to the Citrate Phosphate Dextrose (CPD) buffer allows for ATP regeneration, extending the shelf life to **35 days**. 3. **Whole Blood with CPD at 4°C:** Without adenine, the red cells exhaust their metabolic resources sooner, resulting in a shelf life of **21 days**. 4. **Platelets at 20-24°C:** These have the shortest shelf life of **5 days**. They must be stored at room temperature with constant agitation to maintain viability and prevent "storage lesions," but this increases the risk of bacterial growth. ### **Why the Question asks for the "Shortest" (Descending Order Logic):** The correct sequence from longest to shortest is: **FFP (1 year) > CPDA-1 (35 days) > CPD (21 days) > Platelets (5 days).** Therefore, in a descending list, **CPD (21 days)** is correctly placed after CPDA-1 and before Platelets. ### **High-Yield Clinical Pearls for NEET-PG:** * **SAGM (Saline-Adenine-Glucose-Mannitol):** Extends RBC shelf life to **42 days**. * **Cryoprecipitate:** Stored at -18°C for **1 year** (rich in Factor VIII, Fibrinogen, and vWF). * **Storage Lesion:** Refers to the decrease in pH, 2,3-DPG, and Sodium, and an **increase in Potassium** in stored blood. * **Temperature Check:** Platelets are the only routine component stored at room temperature (20-24°C).

Question 167: Letterer-siwe disease is a disturbance of which of the following?

A. Protein metabolism
B. Histiocytic disorder (Correct Answer)
C. Mucopolysaccharide metabolism
D. Carbohydrate metabolism

Explanation: **Explanation:** **Letterer-Siwe disease** is the most severe, acute multisystem form of **Langerhans Cell Histiocytosis (LCH)** [1]. It is characterized by the neoplastic proliferation of Langerhans cells, which are specialized dendritic cells (histiocytes) normally found in the skin [1]. Because it involves the abnormal proliferation and accumulation of these cells in various organs (skin, bone marrow, liver, and spleen), it is classified as a **Histiocytic disorder**. **Analysis of Options:** * **Option B (Correct):** LCH (including Letterer-Siwe) is defined by the proliferation of cells expressing CD1a, S100, and CD207 (Langerin) [1]. These cells are part of the monocyte-macrophage/histiocyte lineage. * **Option A, C, & D (Incorrect):** These refer to metabolic storage disorders. While conditions like Gaucher’s disease [2] (lipid metabolism) or Hurler syndrome [3] (mucopolysaccharidosis) involve histiocytes (macrophages) accumulating undigested substrates, Letterer-Siwe is a primary proliferative/neoplastic disorder of the cells themselves, not a secondary accumulation due to metabolic enzyme deficiencies. **High-Yield Clinical Pearls for NEET-PG:** * **Age Group:** Typically affects infants and children under 2 years of age. * **Clinical Triad:** Skin rash (seborrheic-like), hepatosplenomegaly, and lymphadenopathy. It often involves the bone marrow, leading to anemia and thrombocytopenia. * **Pathognomonic Feature:** Presence of **Birbeck granules** (tennis-racket shaped organelles) seen on Electron Microscopy [1]. * **Immunohistochemistry (IHC):** Positive for **CD1a**, **S100**, and **Langerin (CD207)** [1]. * **LCH Spectrum:** Includes Letterer-Siwe (multisystem, acute), Hand-Schüller-Christian disease (multifocal, chronic), and Eosinophilic Granuloma (unifocal). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 629-630. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, p. 163. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 163-164.

Question 168: Disseminated Intravascular Coagulation (DIC) is typically seen in which subtype of Acute Myeloid Leukemia (AML)?

A. M1
B. M2
C. M3 (Correct Answer)
D. M6

Explanation: **Explanation:** **Correct Option: C (M3)** Acute Promyelocytic Leukemia (APL), classified as **FAB M3**, is the subtype most strongly associated with **Disseminated Intravascular Coagulation (DIC)** [1]. The underlying mechanism involves the presence of numerous primary granules in the malignant promyelocytes [1]. These granules contain **procoagulants** (like Tissue Factor) and **fibrinolytic enzymes** [2]. When these cells break down (either spontaneously or due to chemotherapy), these substances are released into the circulation, triggering the coagulation cascade and systemic fibrinolysis simultaneously. This leads to the characteristic life-threatening hemorrhagic diathesis. **Incorrect Options:** * **A (M1) & B (M2):** These represent AML with minimal maturation and AML with maturation, respectively. While they are common subtypes, they do not possess the specific procoagulant-rich granules seen in M3 and are not typically associated with primary DIC. * **D (M6):** Also known as Erythroleukemia, this subtype involves the proliferation of erythroid precursors. It is associated with ring sideroblasts and complex cytogenetics but not with DIC. **High-Yield Clinical Pearls for NEET-PG:** * **Cytogenetics:** M3 is characterized by the **t(15;17)** translocation, involving the *PML-RARA* fusion gene [1]. * **Morphology:** Look for **Auer rods**, often found in clusters called **"Faggot cells."** [1] * **Treatment:** The standard of care is **All-trans Retinoic Acid (ATRA)** and Arsenic Trioxide, which induce the differentiation of promyelocytes into mature neutrophils. * **Emergency:** DIC in M3 is a medical emergency; starting ATRA immediately is crucial to halt the coagulopathy. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-622. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 671-673.

Question 169: What is the most common translocation found in follicular lymphomas?

A. t(14;18) (Correct Answer)
B. t(17;19)
C. t(11;14)
D. t(22;09)

Explanation: **Explanation:** **Follicular Lymphoma (FL)** is a B-cell neoplasm derived from germinal center B-cells [3]. The hallmark genetic abnormality, present in approximately 90% of cases, is the **t(14;18)(q32;q21)** translocation [1], [2], [3]. 1. **Why t(14;18) is correct:** This translocation involves the **BCL2 gene** on chromosome 18 and the **IgH (Immunoglobulin Heavy chain) locus** on chromosome 14 [1], [2]. Because the IgH locus is highly active in B-cells, the BCL2 gene is constitutively overexpressed [2], [3]. BCL2 is an anti-apoptotic protein; its overexpression prevents programmed cell death (apoptosis) in germinal center B-cells, leading to their accumulation and the formation of lymphoma [1], [3]. 2. **Analysis of Incorrect Options:** * **t(11;14):** Characteristic of **Mantle Cell Lymphoma**. It involves the *CCND1* (Cyclin D1) gene, leading to cell cycle progression. * **t(22;9):** Known as the **Philadelphia Chromosome**, characteristic of **Chronic Myeloid Leukemia (CML)** and some cases of ALL. It creates the *BCR-ABL1* fusion protein. * **t(17;19):** A rare translocation associated with a subtype of B-cell Acute Lymphoblastic Leukemia (B-ALL). **High-Yield Clinical Pearls for NEET-PG:** * **Morphology:** Characterized by a nodular/follicular growth pattern [3]. Centrocytes (cleaved cells) and centroblasts are the predominant cell types [3]. * **Immunophenotype:** Positive for B-cell markers (CD19, CD20, CD10) and **BCL2**. Note: Normal germinal centers are BCL2 negative; BCL2 positivity in a follicle is diagnostic of FL [1]. * **Clinical Course:** Indolent (slow-growing) but difficult to cure. It can transform into a more aggressive Diffuse Large B-Cell Lymphoma (DLBCL), a phenomenon known as **Richter’s transformation** (though more common in CLL). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 310-311. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 561-562.

Question 170: Mega platelets are characteristic findings in which of the following conditions?

A. Glanzmann thrombasthenia
B. Von Willebrand disease
C. Wiskott-Aldrich syndrome
D. Bernard-Soulier syndrome (Correct Answer)

Explanation: **Explanation:** **Bernard-Soulier Syndrome (BSS)** is the correct answer because it is characterized by the classic triad of **thrombocytopenia, prolonged bleeding time, and giant (mega) platelets**. The underlying defect is a deficiency or dysfunction of the **GPIb-IX-V receptor** complex [1], which is essential for platelet adhesion to subendothelial von Willebrand factor (vWF) [1]. The formation of "giant platelets" (often as large as red blood cells) occurs due to abnormal megakaryocyte maturation and proplatelet formation in the bone marrow. **Analysis of Incorrect Options:** * **Glanzmann Thrombasthenia:** This is a defect in the **GPIIb/IIIa receptor**, leading to impaired platelet aggregation [1]. On a peripheral smear, platelets appear **normal in size and morphology**, but they fail to aggregate with any agonist except ristocetin [1]. * **Von Willebrand Disease (vWD):** This is a quantitative or qualitative deficiency of **vWF**. While it affects platelet adhesion, the **platelet morphology and size remain normal**. * **Wiskott-Aldrich Syndrome:** This X-linked disorder is characterized by the triad of eczema, immunodeficiency, and thrombocytopenia. Crucially, it features **micro-platelets (small platelets)**, which is the morphologic opposite of BSS. **High-Yield Clinical Pearls for NEET-PG:** * **Ristocetin Test:** In BSS, platelet aggregation fails with Ristocetin and **cannot** be corrected by adding normal plasma (unlike vWD, which corrects). * **Differential for Giant Platelets:** Apart from BSS, consider **May-Hegglin anomaly** (look for Dohle-like bodies in neutrophils) and **Immune Thrombocytopenic Purpura (ITP)** (due to rapid turnover). [2] * **Mnemonic:** **B**ernard-**S**oulier = **B**ig **S**ize platelets; **W**iskott-Aldrich = **W**ee (small) platelets. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 668-669. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 666-667.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free